1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Y. Y. Janjigian, Akihito Kawazoe, Yikui Bai, Jiayue Xu, Sara Lonardi, J-P. Metges, P.E. Yanez Weber, Lucjan Wyrwicz, Lin Shen, Y.V. Ostapenko, Muammer Bilici, Hyun Cheol Chung, K. Shitara, Mauricio Mahave, E. Van Cutsem, Josep Tabernero, Lei Xu, Kanu Sharan, Pooja Bhagia, Sun Young Rha